Reassessing therapeutic antibodies for neglected and tropical diseases.

• Egile Nagusiak: Rob Hooft van Huijsduijnen (Egilea), Somei Kojima (Egilea), Dee Carter (Egilea), Hisafumi Okabe (Egilea), Akihide Sato (Egilea), Wataru Akahata (Egilea), Timothy N C Wells (Egilea), Kei Katsuno (Egilea)
• Formatua: Liburua
• Argitaratua: Public Library of Science (PLoS), 2020-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

In the past two decades there has been a significant expansion in the number of new therapeutic monoclonal antibodies (mAbs) that are approved by regulators. The discovery of these new medicines has been driven primarily by new approaches in inflammatory diseases and oncology, especially in immuno-o...